| Year |
Citation |
Score |
| 2008 |
Gehrke BJ, Chefer VI, Shippenberg TS. Effects of acute and repeated administration of salvinorin A on dopamine function in the rat dorsal striatum. Psychopharmacology. 197: 509-17. PMID 18246329 DOI: 10.1007/s00213-007-1067-6 |
0.466 |
|
| 2007 |
Klein ED, Gehrke BJ, Green TA, Zentall TR, Bardo MT. Repeated Cocaine Experience Facilitates Sucrose-Reinforced Operant Responding in Enriched and Isolated Rats. Learning and Motivation. 38. PMID 24347683 DOI: 10.1016/J.Lmot.2006.07.004 |
0.541 |
|
| 2006 |
Gehrke BJ, Cass WA, Bardo MT. Monoamine-depleting doses of methamphetamine in enriched and isolated rats: consequences for subsequent methamphetamine-induced hyperactivity and reward. Behavioural Pharmacology. 17: 499-508. PMID 16940771 DOI: 10.1097/00008877-200609000-00016 |
0.683 |
|
| 2003 |
Gehrke BJ, Harrod SB, Cass WA, Bardo MT. The effect of neurotoxic doses of methamphetamine on methamphetamine-conditioned place preference in rats. Psychopharmacology. 166: 249-57. PMID 12589519 DOI: 10.1007/S00213-002-1318-5 |
0.643 |
|
| 2003 |
Bardo MT, Gehrke BJ, Shortridge BE, Rauhut AS. Effects of beta-funaltrexamine and naloxonazine on single-trial morphine-conditioned place preference and locomotor activity. Pharmacology, Biochemistry, and Behavior. 74: 617-22. PMID 12543227 DOI: 10.1016/S0091-3057(02)01049-3 |
0.611 |
|
| 2003 |
Harrod SB, Dwoskin LP, Green TA, Gehrke BJ, Bardo MT. Lobeline does not serve as a reinforcer in rats. Psychopharmacology. 165: 397-404. PMID 12459929 DOI: 10.1007/S00213-002-1289-6 |
0.644 |
|
| 2002 |
Green TA, Gehrke BJ, Bardo MT. Environmental enrichment decreases intravenous amphetamine self-administration in rats: dose-response functions for fixed- and progressive-ratio schedules. Psychopharmacology. 162: 373-8. PMID 12172690 DOI: 10.1007/S00213-002-1134-Y |
0.675 |
|
| 2002 |
Rauhut AS, Gehrke BJ, Phillips SB, Bardo MT. Effects of opioid antagonists on unconditioned and conditioned hyperactivity to morphine. Pharmacology, Biochemistry, and Behavior. 73: 611-22. PMID 12151036 DOI: 10.1016/S0091-3057(02)00855-9 |
0.527 |
|
| Low-probability matches (unlikely to be authored by this person) |
| 2022 |
Kim N, Norsworthy KJ, Subramaniam S, Chen H, Manning ML, Kitabi E, Earp J, Ehrlich LA, Okusanya OO, Vallejo J, Gehrke BJ, de Claro RA, Pazdur R. FDA approval summary: decitabine and cedazuridine tablets for myelodysplastic syndromes. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 35435961 DOI: 10.1158/1078-0432.CCR-21-4498 |
0.169 |
|
| 2008 |
Schepers RJ, Mahoney JL, Gehrke BJ, Shippenberg TS. Endogenous kappa-opioid receptor systems inhibit hyperalgesia associated with localized peripheral inflammation. Pain. 138: 423-39. PMID 18355964 DOI: 10.1016/j.pain.2008.01.023 |
0.135 |
|
| 2022 |
Jen EY, Wang X, Li M, Li H, Lee SL, Ni N, Przepiorka D, Vallejo J, Leong R, Ma L, Gehrke BJ, McLamore S, Theoret MR, de Claro RA. FDA Approval Summary: Oral Azacitidine For Continued Treatment of Adults with Acute Myeloid Leukemia Unable to Complete Intensive Curative Therapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 35325108 DOI: 10.1158/1078-0432.CCR-21-4525 |
0.11 |
|
| 2014 |
Malik SM, Maher VE, Bijwaard KE, Becker RL, Zhang L, Tang SW, Song P, Liu Q, Marathe A, Gehrke B, Helms W, Hanner D, Justice R, Pazdur R. U.S. Food and Drug Administration approval: crizotinib for treatment of advanced or metastatic non-small cell lung cancer that is anaplastic lymphoma kinase positive. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 2029-34. PMID 24573551 DOI: 10.1158/1078-0432.CCR-13-3077 |
0.106 |
|
| 2012 |
Thornton K, Kim G, Maher VE, Chattopadhyay S, Tang S, Moon YJ, Song P, Marathe A, Balakrishnan S, Zhu H, Garnett C, Liu Q, Booth B, Gehrke B, Dorsam R, et al. Vandetanib for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease: U.S. Food and Drug Administration drug approval summary. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 3722-30. PMID 22665903 DOI: 10.1158/1078-0432.CCR-12-0411 |
0.104 |
|
| 2015 |
Deisseroth A, Ko CW, Nie L, Zirkelbach JF, Zhao L, Bullock J, Mehrotra N, Del Valle P, Saber H, Sheth C, Gehrke B, Justice R, Farrell A, Pazdur R. FDA approval: siltuximab for the treatment of patients with multicentric Castleman disease. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 950-4. PMID 25601959 DOI: 10.1158/1078-0432.CCR-14-1678 |
0.052 |
|
| 2015 |
Przepiorka D, Ko CW, Deisseroth A, Yancey CL, Candau-Chacon R, Chiu HJ, Gehrke BJ, Gomez-Broughton C, Kane RC, Kirshner S, Mehrotra N, Ricks TK, Schmiel D, Song P, Zhao P, et al. FDA Approval: Blinatumomab. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 4035-9. PMID 26374073 DOI: 10.1158/1078-0432.CCR-15-0612 |
0.036 |
|
| 2009 |
Zapata A, Schepers R, Gehrke B, Oh E, Trullas R, Shippenberg T. 213 NEURONAL PENTRAXIN 1 CONTRIBUTES TO THE DESCENDING MODULATION OF NEUROPATHIC PAIN European Journal of Pain. 13: S69. DOI: 10.1016/S1090-3801(09)60216-0 |
0.01 |
|
| Hide low-probability matches. |